Reports Q3 revenue $9.3M. “We are excited about the potential of PEMGARDA to address the significant unmet need of COVID-19 pre-exposure prophylaxis for certain immunocompromised people and expect that ongoing commercial execution will drive substantial revenue growth and market expansion,” said Tim Lee, Chief Commercial Officer of Invivyd (IVVD). “We have expanded our outreach efforts – driving awareness of PEMGARDA in the healthcare providers community, increasing our ability to reach to additional points of care, and adding new programs to support patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IVVD:
- Invivyd announces NEJM published letter to editor on PEMGARDA
- Invivyd announces manuscript preprint conveying data from CANOPY Phase 3 trial
- IVVD Upcoming Earnings Report: What to Expect?
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Alphabet upgraded, Boeing downgraded: Wall Street’s top analyst calls
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
